Saxagliptin Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 2.5 mg, 5 mg
Reference Brands: Onglyza®(US & EU)
Category:
Diabetes
Saxagliptin inhibits DPP-4, enhancing incretin hormones to boost insulin secretion and reduce glucagon levels in a glucose-dependent manner. Benefits include improved glycemic control, low hypoglycemia risk, weight neutrality, and once-daily oral dosing. Suitable as monotherapy or in combination therapy.
Saxagliptin tablets is available in Tablets
and strengths such as 2.5 mg, 5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Saxagliptin tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Saxagliptin tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Saxagliptin oral tablets, marketed as Onglyza®, are FDA-approved in the USA and EMA-authorized in the EU for managing type 2 diabetes. Also available in combination with metformin as Kombiglyze XR® (USA) and Komboglyze® (EU), these DPP-4 inhibitors require full compliance with GMP, pharmacovigilance, and post-marketing safety reporting. US regulations mandate NDA approval under 21 CFR, with heart failure warnings. In the EU, approval follows the centralized procedure with CTD submissions and Risk Management Plans (RMPs). For compliant sourcing, regulatory support, or B2B pharmaceutical trade, visit PharmaTradz.com – your trusted partner in global pharma solutions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing